425: Alumis and ACELYRIN Announce Merger to Strengthen Financial Position and Advance Clinical Pipeline

Alumis and ACELYRIN have announced a merger, creating a combined entity with approximately $737 million in cash to fund operations into 2027 and advance their respective clinical programs.

Summary

• Alumis and ACELYRIN have announced a definitive agreement to merge in an all-stock transaction.
• The merger aims to strengthen Alumis' financial foundation to advance its clinical programs through trials and into commercialization.
• The combined company will have a pro forma cash position of approximately $737 million as of year-end 2024, providing runway into 2027.
• Alumis will evaluate the development strategy for ACELYRIN's lonigutamab program to ensure capital efficiency.
• Alumis' existing development programs, including the Phase 3 ONWARD clinical program and Phase 2b LUMUS clinical trial for ESK-001, and the Phase 2 clinical trial for A-005 in MS, will continue as planned, with topline data readouts expected in 2026.
• The transaction is expected to close in the second quarter of 2025, pending stockholder approvals and customary closing conditions.
• Following the closing, the combined company will operate under the Alumis name, headquartered in San Francisco, with the current Alumis management team leading the company.
• Stockholders representing approximately 62% of Alumis voting common stock and approximately 24% of ACELYRIN common stock have entered into voting agreements in support of the transaction.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook due to the increased financial stability and continued development of clinical programs following the merger. The emphasis on capital efficiency and the experience of the existing management team further contribute to the positive sentiment.

Positives

• The merger strengthens Alumis' financial position, providing a longer cash runway into 2027.
• The combined company will have a more robust pipeline with the addition of ACELYRIN's lonigutamab program.
• Alumis' existing clinical programs will continue without interruption.
• The current Alumis management team will lead the combined company, ensuring continuity.
• Key members of ACELYRIN's team will join Alumis, bringing additional expertise.

Risks

• The merger may not be completed in a timely manner or at all.
• Required approvals, including stockholder approvals, may not be obtained.
• The announcement or completion of the merger could negatively impact Alumis' or ACELYRIN's ability to attract and retain key personnel.
• The merger could divert management's attention from ongoing business operations.
• Legal proceedings related to the merger could arise.
• The anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.
• Integration of the two companies post-closing may not occur as anticipated.
• The value of Alumis securities to be issued in the proposed transaction could be affected.

Future Outlook

The combined company expects to advance its clinical pipeline and achieve multiple clinical data readouts, with sufficient cash to fund operations into 2027.

Management Comments

• A core focus of the leadership team is to strengthen our financial foundation to provide the runway to advance our programs through our current trials and into commercialization.
• This transaction with ACELYRIN helps us achieve just that.
• Through this transaction, we will be well positioned to execute on the promise of our highly differentiated portfolio and the significant benefits that our molecules can bring to patients with immune-mediated diseases.

Industry Context

The merger reflects a trend in the biopharmaceutical industry to consolidate resources and pipelines to enhance financial stability and accelerate drug development.

Comparison to Industry Standards

• Similar mergers in the biopharmaceutical sector often aim to diversify pipelines and reduce financial risk, such as Pfizer's acquisition of Arena Pharmaceuticals to expand its immunology portfolio.
• The combined cash position of $737 million is comparable to other mid-sized biopharmaceutical companies, providing a competitive advantage in funding clinical trials and research and development.
• The focus on capital efficiency in developing lonigutamab aligns with industry best practices to maximize returns on investment in drug development.

Stakeholder Impact

• Shareholders of both Alumis and ACELYRIN will be impacted by the merger, requiring them to vote on the transaction.
• Employees of both companies will be affected by the integration, although no significant changes to roles and responsibilities are currently anticipated.
• Patients may benefit from the accelerated development of new therapies due to the combined resources of the two companies.
• Partners and collaborators can expect continued engagement with Alumis, with a stronger financial position to support ongoing projects.

Next Steps

• Obtain stockholder approvals from both Alumis and ACELYRIN.
• Satisfy customary closing conditions.
• File a registration statement on Form S-4 with the SEC, including a joint proxy statement/prospectus.
• Evaluate the development strategy for ACELYRIN's lonigutamab program.
• Integrate ACELYRIN's team and operations into Alumis following the closing.

Key Dates